Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai Ruijing Biotechnology

Explore full profile

Focuses on the molecular diagnosis of thyroid tumors

Minhang District, ChinaFounded 2017Biotech & Life Sciences
Valuation $50–100M Last recorded · 2025
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Shanghai Ruijing Biotechnology and the history behind them.

About Shanghai Ruijing Biotechnology

Shanghai Ruijing Biotechnology Co., Ltd. (Rigen Bio), established in August 2017, is a high-tech enterprise focused on providing molecular diagnostic solutions for precision medicine, with a particular specialization in thyroid cancer. The company was founded by Mr. Hong Gendong, who serves as the legal representative and brings over two decades of experience in commercializing clinical products and team management, including a successful career at Boehringer Ingelheim. His commercial expertise is complemented by a strong R&D team led by CSO Dr. Yang Feng, a Peking University molecular medicine Ph.D., and CTO Dr. Shi Han, a Tsinghua University graduate with a Ph.D. from Northwestern University.

The company operates in the rapidly growing field of in-vitro diagnostics (IVD), specifically targeting the significant clinical need for better diagnosis and management of thyroid nodules and cancer. Its business model integrates the entire process from research and development to manufacturing, sales, and service. Rigen Bio generates revenue by selling its diagnostic products and providing testing services to healthcare institutions. Its client base primarily consists of large, top-tier (Class A Grade 3) general and specialized cancer hospitals across more than fifteen provinces in China.

Rigen Bio has developed a comprehensive product portfolio that covers the entire clinical pathway for thyroid cancer, from initial diagnosis to post-operative monitoring. A cornerstone achievement is the 2023 NMPA approval of its “Human BRAF/TERT/CCDC6-RET Gene Mutation Detection Kit (Fluorescence PCR method),” the first-of-its-kind product approved in China for pre-operatively assessing indeterminate thyroid nodules. The company's offerings also include a specially designed disposable thyroid biopsy needle, various multi-gene qPCR and Next-Generation Sequencing (NGS) testing kits, and the Thyroscan® classifier, which uses machine learning to assess nodule malignancy. These products provide an integrated solution for physicians, aiding in the accurate classification of thyroid nodules, which helps to avoid unnecessary surgeries and reduces the burden on healthcare resources.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2017
Headquarters
Minhang District, China
Employees
5
Open positions
None listed
Dealroom signal
25.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
b2c

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Nov 2025 $14M $55M Efung Capital ↗
EARLY VC✓Equity / VC Nov 2023 $2.8M $69M Boyuan Capital · Jinsheng Investment ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Shanghai Ruijing Biotechnology website traffic

Latest recorded traffic for Shanghai Ruijing Biotechnology is 410 monthly website visits, up 127.8% over the last three months. Shanghai Ruijing Biotechnology's team grew 0% over the past year.

Latest monthly visits410 3-month web change+127.8% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Guotai Junan Innovation Investment
  • Jinsheng Investment
  • Boyuan Capital
  • Efung Capital
Employees 5 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai Ruijing Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Ruijing Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.